Research progress of conversion therapy in colorectal cancer liver metastases.
10.3760/cma.j.cn.441530-20200311-00135
- Author:
Yu Yang ZHANG
1
;
Shan Wen CHEN
1
;
Peng Yuan WANG
1
;
Yu Cun LIU
1
Author Information
1. Department of General Surgery, Peking University First Hospital, Beijing 100034, China.
- Publication Type:Review
- Keywords:
Colorectal cancer liver metastases;
Conversion therapy;
Immune checkpoint inhibitors;
Locoregional therapy;
Targeted therapy
- MeSH:
Biomedical Research;
Colorectal Neoplasms/therapy*;
Combined Modality Therapy/methods*;
Hepatectomy;
Humans;
Liver Neoplasms/therapy*;
Prognosis
- From:
Chinese Journal of Gastrointestinal Surgery
2021;24(1):85-93
- CountryChina
- Language:Chinese
-
Abstract:
The probability of developing liver metastases in patients with colorectal cancer is 40%-50%. Liver metastases remain an important adverse factor affecting long-term prognosis of colorectal cancer patients. Surgical resection of liver metastases is the only potentially curative treatment option. After comprehensive treatment, initially unresectable liver metastases might be converted to resectable tumors. This concept is known as conversion therapy. In this review, research status of conversion therapy in colorectal cancer liver metastases was summarized, providing updated concept of resectability, discussions on the assessment of tumor response and timing of operation, debates on the influence on tumor sidedness, and latest advancement in the treatment strategy of conversion therapy. Through analyzing existing problems, we hope to offer insights into possible progress in the future and provide references for the development of clinical practice.
